Top

Category: Pharma


Industry, Pharma

The Considered pharmaceutical marketing experiment

December 23, 2021

Via: Pharmaphorum

“There is some brilliant work that takes place by some incredibly intelligent agencies and individuals, but I know how formulaic we’ve become as an industry where next year’s tactics are probably very similar to this year’s tactics,” he says. “What […]


Industry, Pharma

Pharmaceutical Manufacturing And Packaging Congress 2022 Connects Pharma Leaders

November 29, 2021

Via: Pharmaphorum

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) covers the current state of the pharmaceutical manufacturing and packaging industry. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies. It will take place […]


Industry, Pharma

Gilead pays up to retain rights to Arcus cancer drugs

November 18, 2021

Via: Biopharma Dive

The initial deal between Gilead and Arcus gave the larger drugmaker rights to an experimental drug called zimberelimab, which attacks cancers using the same mechanism as Keytruda, along with an option to license the four projects covered by Thursday’s announcement. […]


Industry, Pharma

Cortexyme plans path forward for Alzheimer’s drug that failed study

November 12, 2021

Via: Biopharma Dive

Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer’s drug in another study, convinced that signs of benefit observed in some patients are proof its treatment works. […]


Industry, Pharma

US buys another $1 billion-worth of Merck’s COVID capsule

November 10, 2021

Via: Pharmaphorum

The latest agreement – worth around $1 billion – means that the US has now called dibs on 3.1 million doses of molnupiravir, which was approved in the UK as a treatment for people with mild to moderate COVID-19 who […]


Industry, Pharma

UPDATE: Pfizer’s oral COVID-19 antiviral cuts hospitalization, death by 85%, sending team barreling to FDA

November 5, 2021

Via: FierceBiotech

Pfizer’s oral COVID-19 antiviral Paxlovid has cut the risk of hospitalization or death by 85% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA. Merck showed oral […]


Industry, Pharma

EMA starts rolling review of Merck’s molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data

October 25, 2021

Via: FierceBiotech

Merck has opened another front in its campaign to get molnupiravir to market, kicking off a process that could lead to the approval of the oral COVID-19 antiviral in the EU. Things have moved quickly since Merck and partner Ridgeback […]


Industry, Pharma

Merck preps filings for oral COVID drug, but is it really a game changer?

October 4, 2021

Via: Pharmaphorum

Merck and partner Ridgeback Therapeutics have said they will see emergency use authorisation from the FDA for molnupiravir on the strength of the data, which suggest the drug could be used in the community to keep people from developing severe […]


Industry, Pharma

Merck’s oral COVID-19 antiviral slashes hospitalizations, prevents deaths in phase 3, sparking race to file with FDA

October 1, 2021

Via: FierceBiotech

The wait for an oral antiviral against COVID-19 may almost be over. Friday, Merck reported its prospect halved the risk of hospitalization and death in phase 3, spurring it to stop the study and race to get emergency use authorization. […]


Clinical Trials, Industry, Pharma, Research and Development

Pfizer drug bests Sanofi, Regeneron’s Dupixent in head-to-head study

August 30, 2021

Via: Biopharma Dive

Abrocitinib is one of Pfizer’s top experimental therapies, pegged by the drugmaker for several billion dollars in peak annual sales in the future. But its fate, along with the fate of two other drugs from AbbVie and Lilly that are […]


Industry, Pharma

Pharmacies Face Extra Audit Burdens That Threaten Their Existence

August 6, 2021

Via: Kaiser Health News

The clock was about to strike midnight, and Scott Newman was desperately feeding pages into a scanner, trying to prevent thousands of dollars in prescription payments from turning into a pumpkin. As the owner of Newman Family Pharmacy, an independent […]


Industry, Pharma

Pfizer’s immunology ambitions delayed—again—as JAK drugs fall victim to FDA’s protracted safety review

July 22, 2021

Via: FiercePharma

Pfizer and its JAK inhibitors are falling deeper down a regulatory rabbit hole the company itself opened up. The FDA has once again pushed back two decisions key to Pfizer’s immunology franchise: Xeljanz in ankylosing spondylitis and abrocitinib in atopic […]